Published in JAMA on August 18, 1999
A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health (2008) 8.49
Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med (2003) 7.99
Comprehensive identification of conditionally essential genes in mycobacteria. Proc Natl Acad Sci U S A (2001) 6.22
Cell-mediated immune responses in tuberculosis. Annu Rev Immunol (2009) 5.90
Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol (2003) 5.68
Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis (2011) 5.34
Prospective study of one million deaths in India: rationale, design, and validation results. PLoS Med (2005) 5.05
Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proc Natl Acad Sci U S A (2004) 4.98
Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc Natl Acad Sci U S A (2003) 4.64
Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis (2005) 4.36
Paediatric tuberculosis. Lancet Infect Dis (2008) 3.97
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med (2006) 3.81
Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev (2006) 3.79
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother (2003) 3.76
Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis. J Med Chem (2006) 3.75
Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev (2011) 3.63
The temporal expression profile of Mycobacterium tuberculosis infection in mice. Proc Natl Acad Sci U S A (2004) 3.63
A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med (2011) 3.60
Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov (2013) 3.50
Global trends in antimicrobial use in food animals. Proc Natl Acad Sci U S A (2015) 3.46
Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect Immun (2000) 3.39
Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings. J Clin Microbiol (2004) 3.27
Tuberculosis: latency and reactivation. Infect Immun (2001) 3.15
Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci U S A (2003) 3.14
Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS One (2008) 3.07
Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A (2000) 3.07
Genomic DNA standards for gene expression profiling in Mycobacterium tuberculosis. Nucleic Acids Res (2002) 2.94
Assessment by meta-analysis of PCR for diagnosis of smear-negative pulmonary tuberculosis. J Clin Microbiol (2003) 2.93
Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med (2004) 2.83
Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc Natl Acad Sci U S A (2003) 2.80
Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH. Proc Natl Acad Sci U S A (2002) 2.76
Replication dynamics of Mycobacterium tuberculosis in chronically infected mice. Infect Immun (2005) 2.74
Two sensor kinases contribute to the hypoxic response of Mycobacterium tuberculosis. J Biol Chem (2004) 2.71
Genetic biodiversity of Mycobacterium tuberculosis complex strains from patients with pulmonary tuberculosis in Cameroon. J Clin Microbiol (2003) 2.69
An immeasurable crisis? A criticism of the millennium development goals and why they cannot be measured. PLoS Med (2005) 2.59
Tuberculosis and HIV co-infection. PLoS Pathog (2012) 2.57
Mycobacterium tuberculosis DosS is a redox sensor and DosT is a hypoxia sensor. Proc Natl Acad Sci U S A (2007) 2.55
Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci U S A (2000) 2.46
Diagnosing sputum/smear-negative pulmonary tuberculosis: Does fibre-optic bronchoscopy play a significant role? Lung India (2010) 2.43
Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth. Proc Natl Acad Sci U S A (2002) 2.41
The alternative sigma factor SigH regulates major components of oxidative and heat stress responses in Mycobacterium tuberculosis. J Bacteriol (2001) 2.40
Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 2.39
Using GIS technology to identify areas of tuberculosis transmission and incidence. Int J Health Geogr (2004) 2.37
The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev (2008) 2.36
New measurable indicator for tuberculosis case detection. Emerg Infect Dis (2004) 2.34
Identification of mycobacteria by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. J Clin Microbiol (2006) 2.34
Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med (2008) 2.33
Mycobacterial interspersed repetitive unit typing of Mycobacterium tuberculosis compared to IS6110-based restriction fragment length polymorphism analysis for investigation of apparently clustered cases of tuberculosis. J Clin Microbiol (2003) 2.33
Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. J Clin Microbiol (2001) 2.28
Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med (2006) 2.28
Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study. Lancet (2008) 2.27
Challenging issues in tuberculosis in solid organ transplantation. Clin Infect Dis (2013) 2.27
Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 2.21
Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun (2001) 2.21
Mycobacterium tuberculosis signal transduction system required for persistent infections. Proc Natl Acad Sci U S A (2001) 2.17
Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax (2002) 2.12
Tetracycline-inducible gene regulation in mycobacteria. Nucleic Acids Res (2005) 2.12
Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med (2010) 2.10
DOTS improves treatment outcomes and service coverage for tuberculosis in South Ethiopia: a retrospective trend analysis. BMC Public Health (2005) 2.09
A member of the cAMP receptor protein family of transcription regulators in Mycobacterium tuberculosis is required for virulence in mice and controls transcription of the rpfA gene coding for a resuscitation promoting factor. Mol Microbiol (2005) 2.08
Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev (2012) 2.07
FIDELIS--innovative approaches to increasing global case detection of tuberculosis. Am J Public Health (2005) 2.06
Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun (2003) 2.06
Sigma factors and global gene regulation in Mycobacterium tuberculosis. J Bacteriol (2004) 2.05
Heme oxygenase-1-derived carbon monoxide induces the Mycobacterium tuberculosis dormancy regulon. J Biol Chem (2008) 2.04
Eliminating human tuberculosis in the twenty-first century. J R Soc Interface (2008) 2.00
A novel lipase belonging to the hormone-sensitive lipase family induced under starvation to utilize stored triacylglycerol in Mycobacterium tuberculosis. J Biol Chem (2005) 1.99
GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism. Genome Biol (2007) 1.99
Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy. J Clin Invest (2000) 1.98
Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis (2010) 1.97
Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J Clin Microbiol (2002) 1.96
Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy. Clin Microbiol Rev (2004) 1.95
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun (2004) 1.90
Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol (2005) 1.88
Mycobacterium tuberculosis WhiB3 maintains redox homeostasis by regulating virulence lipid anabolism to modulate macrophage response. PLoS Pathog (2009) 1.87
Measuring health-related quality of life in tuberculosis: a systematic review. Health Qual Life Outcomes (2009) 1.85
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother (2003) 1.85
rpoB genotypes of Mycobacterium tuberculosis Beijing family isolates from East Asian countries. J Clin Microbiol (2002) 1.83
A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun (2003) 1.81
Comprehensive health care for people infected with HIV in developing countries. BMJ (2002) 1.81
Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun (2003) 1.81
A family of acr-coregulated Mycobacterium tuberculosis genes shares a common DNA motif and requires Rv3133c (dosR or devR) for expression. Infect Immun (2003) 1.80
Will tuberculosis become resistant to all antibiotics? Proc Biol Sci (2001) 1.79
CT features in abdominal tuberculosis: 20 years experience. BMC Med Imaging (2002) 1.79
Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China. J Clin Microbiol (2005) 1.78
Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol (2006) 1.76
Did we reach the 2005 targets for tuberculosis control? Bull World Health Organ (2007) 1.76
Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci U S A (2012) 1.74
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis (2015) 1.74
Guidelines for the investigation and follow-up of individuals under medical surveillance for tuberculosis after arriving in Canada: a summary. CMAJ (2003) 1.74
Analysis of the allelic diversity of the mycobacterial interspersed repetitive units in Mycobacterium tuberculosis strains of the Beijing family: practical implications and evolutionary considerations. J Clin Microbiol (2004) 1.74
Has the DOTS strategy improved case finding or treatment success? An empirical assessment. PLoS One (2008) 1.74
Improving the estimation of tuberculosis infection prevalence using T-cell-based assay and mixture models. Int J Tuberc Lung Dis (2008) 1.72
Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China. J Clin Microbiol (2003) 1.71
The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol (2005) 1.71
Mutants of Mycobacterium tuberculosis lacking three of the five rpf-like genes are defective for growth in vivo and for resuscitation in vitro. Infect Immun (2005) 1.70
Comparison of the COBAS AMPLICOR MTB and BDProbeTec ET assays for detection of Mycobacterium tuberculosis in respiratory specimens. J Clin Microbiol (2005) 1.70
Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (1998) 10.78
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J (2011) 8.96
Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA (2000) 8.42
Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ (1994) 6.11
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Zoonotic tuberculosis due to Mycobacterium bovis in developing countries. Emerg Infect Dis (1998) 5.51
Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis (1997) 4.02
Private practitioners and public health: weak links in tuberculosis control. Lancet (2001) 3.99
HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis (1992) 3.95
125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J (2007) 3.67
Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis (2001) 3.51
Public health. Responding to market failures in tuberculosis control. Science (2001) 3.12
Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis (2008) 2.55
Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J (2007) 2.46
Causes of suppurative keratitis in Ghana. Br J Ophthalmol (1995) 2.17
Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA (1995) 2.08
Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis (1993) 2.07
Tuberculosis control in Europe and international migration. Eur Respir J (1994) 2.07
Progress in global tuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. Global Monitoring and Surveillance Project. Int J Tuberc Lung Dis (1999) 1.90
Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy. Int J Tuberc Lung Dis (2002) 1.86
European union standards for tuberculosis care. Eur Respir J (2012) 1.73
Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tuber Lung Dis (1994) 1.71
Nationwide prevalence study of hypertension and related non-communicable diseases in The Gambia. Trop Med Int Health (1997) 1.65
Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS (2000) 1.52
Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS (1995) 1.48
Standardization of antituberculosis drug resistance surveillance in Europe. Recommendations of a World Health Organization (WHO) and International Union Against Tuberculosis and Lung Disease (IUATLD) Working Group. Eur Respir J (2000) 1.45
Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J (1999) 1.42
Polyarteritis nodosa presenting as acute blindness. Ann Emerg Med (1994) 1.38
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med (1994) 1.35
Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am J Respir Crit Care Med (1998) 1.30
Validation of the surveillance system for new cases of tuberculosis in a province of northern Italy. Varese Tuberculosis Study Group. Eur Respir J (1995) 1.25
Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. Eur Respir J (2004) 1.21
Improving the TB case management: The International Standards for Tuberculosis Care. Eur Respir J (2006) 1.19
Determinants of attendance and patient satisfaction at eye clinics in south-western Uganda. Health Policy Plan (1999) 1.19
Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)? Int J Tuberc Lung Dis (2001) 1.18
Drug resistant tuberculosis among the homeless in New York City. N Y State J Med (1990) 1.17
Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol (2000) 1.12
Dynamics and control of the global tuberculosis epidemic. Curr Opin Pulm Med (2000) 1.10
Tuberculosis care in community care organizations in sub-Saharan Africa: practice and potential. Int J Tuberc Lung Dis (1997) 1.08
Costs and benefits of improving tuberculosis control: the case of Thailand. Soc Sci Med (1997) 1.06
DOTS expansion: will we reach the 2005 targets? Int J Tuberc Lung Dis (2004) 1.05
Causes and prevalence of non-vision impairing ocular conditions among a rural adult population in sw Uganda. Ophthalmic Epidemiol (1999) 1.04
Prevention of N-nitrosodiethylamine-induced lung tumorigenesis by ellagic acid and quercetin in mice. Food Chem Toxicol (1999) 0.99
Supervised preventive therapy for latent tuberculosis infection in illegal immigrants in Italy. Am J Respir Crit Care Med (2000) 0.96
Antituberculosis drug resistance: is it worth measuring? The WHO/IUATLD Working Group on Antituberculosis Drug Resistance Surveillance. Monaldi Arch Chest Dis (1996) 0.94
Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC). Eur Respir J (2011) 0.90
Immunomodulatory and cytoprotective role of RP-1 in gamma-irradiated mice. Mol Cell Biochem (2003) 0.86
S. aureus nasal carriage among homosexual men with and without HIV infection. Am J Infect Control (1991) 0.86
Influence of Podophyllum hexandrum on endogenous antioxidant defence system in mice: possible role in radioprotection. J Ethnopharmacol (2001) 0.85
Preventing and managing antimicrobial resistance: imperative for chest physicians. Eur Respir J (2011) 0.84
Isoniazid preventive treatment: predictors of adverse events and treatment completion. Int J Tuberc Lung Dis (2013) 0.83
Helicobacter pylori infection in patients with acquired immune deficiency syndrome. Am J Gastroenterol (1990) 0.83
Cost-comparison of different management policies for tuberculosis patients in Italy. AIPO TB Study Group. Bull World Health Organ (1999) 0.83
Cost-effectiveness analysis of tuberculosis control policies in Ivanovo Oblast, Russian Federation. Ivanovo Tuberculosis Project Study Group. Bull World Health Organ (1998) 0.82
Non-trachomatous corneal opacities in the Gambia--aetiology and visual burden. Eye (Lond) (2002) 0.81
[Burn shock fluid resuscitation and hemodynamic monitoring]. Chirurg (2004) 0.81
Update on the global epidemiology of tuberculosis. Curr Issues Public Health (1996) 0.79
Pneumocystis carinii in bone marrow. Ann Intern Med (1988) 0.78
Drug-resistant tuberculosis in AIDS. Chest (1990) 0.78
Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis (2000) 0.78
Appearance of chloroquine-resistant falciparum malaria in Swaziland. Lancet (1987) 0.78
Preventive therapy for tuberculosis in HIV-infected persons: analysis of policy options based on tuberculin status and CD4+ cell count. Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). Arch Intern Med (1998) 0.77
Pneumocystis carinii infection of the thyroid in a hypothyroid patient with AIDS: diagnosis by fine needle aspiration biopsy. J Clin Endocrinol Metab (1991) 0.76
Pregnancy and breast cancer: a possible explanation for the negative association. Med Hypotheses (1992) 0.76
Confirmation that neither cyanide intoxication nor mutations commonly associated with Leber's Hereditary Optic Neuropathy are implicated in Tanzanian Epidemic Optic Neuropathy. J Neurol Sci (1997) 0.75
Improved bacteriological data are needed to give uniform reporting of tuberculosis in Europe. BMJ (1998) 0.75
Use of sunbeds increases risk of intraocular malignant melanoma. BMJ (1995) 0.75
The future may not be so dark. Int J Tuberc Lung Dis (2001) 0.75
Informed patient consent for defaulter tracing: should we obtain it? Int J Tuberc Lung Dis (2009) 0.75
Splenectomy in patients with AIDS. Am J Hematol (1989) 0.75
Intermittent co-trimoxazole prophylaxis against Pneumocystis carinii pneumonia. Lancet (1990) 0.75
Pleural Pneumocystis carinii infection. Chest (1991) 0.75
Breast carcinoma in a man following local trauma. N Y State J Med (1987) 0.75
[Prevention of Pneumocystis carinii pneumonia with intermittent trimethoprim-sulfamethoxazole]. Minerva Med (1992) 0.75
Prospective multicentre study on the evaluation of antituberculosis treatment results in Italy: comparison of the culture- versus the smear-based methods. National AIPO Tuberculosis Study Group. Eur Respir J (1999) 0.75
Association of tuberculosis risk with the degree of tuberculin reaction in HIV-infected patients. The Gruppo Italiano di Studio Tubercolosi e AIDS. Arch Intern Med (1997) 0.75